Research Benefits of CJC-1295 no DAC
Increased Muscle Growth: According to Canada studies, by stimulating the release of growth hormone, CJC without DAC can potentially enhance muscle mass and strength.
Fat Loss: Some studies suggest that CJC-1295 without Drug Affinity Complex may help reduce body fat by promoting lipolysis, the process by which the body breaks down fats to use as energy. Its metabolic regulation further supports its use in obesity management and improving metabolic health, making it a promising option for effective weight management.
Increased Bone Density: Growth hormone also plays a role in bone health. By stimulating its production, research on CJC without DAC indicates it may help increase bone density, reducing the risk of fractures and osteoporosis.
Cognition and Memory: Emerging Canada scientific research suggests that the peptide may enhance cognition and memory by influencing growth hormone (GH) levels, which support neurogenesis and neuronal health. This is particularly important for aging populations experiencing cognitive decline.
Improved GH levels may enhance memory retention and learning, while better sleep quality from CJC without drug affinity complex could further aid cognitive function, offering benefits for both physical performance and mental acuity.
Enhanced Skin Health: As we age, growth hormone production decreases, leading to signs of skin aging like wrinkles and reduced elasticity.
Canada Research suggests the peptide may help counter these effects by boosting growth hormone secretion, which supports cellular regeneration and collagen synthesis.
This GHRH peptide shows promise in anti-aging therapies, potentially offering firmer skin, improved elasticity, and fewer fine lines and wrinkles.
Wound Healing and Tissue Repair: Canada Studies suggest mod GRF may also play a significant role in wound healing and tissue health by stimulating gh secretion, which is crucial for cellular repair and regeneration.
It promotes fibroblast proliferation (the cells responsible for synthesising extracellular matrix and collagen), enhances nutrient transport, and improves metabolic function, supporting natural healing processes.
Canada Research suggests that GHRH analogs like CJC without the added drug affinity complex may accelerate recovery from injuries and improve tissue repair, potentially benefiting individuals with chronic healing conditions.
Promotion of Protein Synthesis: Laboratory experimentation has demonstrated that the peptide can promote protein synthesis, a crucial process for muscle growth and recovery.
Potential Cardiovascular Benefits: Preliminary research suggests that the peptide may also positively affect cardiovascular health by modulating growth hormone levels, potentially improving heart function and reducing risk factors for heart attacks, such as inflammation and arterial stiffness.
Buy CJC-1295 no DAC Peptide Vial for research online today! This lyophilized product requires reconstitution with bacteriostatic water which you can purchase here along with other necessary supplies for laboratory use.
References For Further Reading
(1) S L Teichman, A Neale, B Lawrence, C Gagnon, JP Castaigne, and L A Frohman (2005) Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults – The Journal of Clinical Endocrinology and Metabolism, 2006 Mar, Volume 91 (Issue 3), Pages 799-805.
(2) M Ionescu and L A Frohman (2006) Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog – J Clin Endocrinol Metab, Volume 91, Issue 12, 1 December 2006, Pages 4792–4797.
(3) M Alba, D Fintini, A Sagazio, B Lawrence, JP Castaigne, L A Frohman, R Salvatori (2006) Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse – American Journal of Physiology. Endocrinology and Metabolism, 2006 Dec, Volume 291 (Issue 6), Pages E1290-4.
(4) F Liao, T J Zhang, T E Mahan, H Jiang, and D M Holtzman (2015) Effects of growth hormone–releasing hormone on sleep and brain interstitial fluid amyloid-β in an APP transgenic mouse model – Brain, Behavior, and Immunity, Volume 47, July 2015, Pages 163-171.
(5) L Sackmann-Sala, J Ding, L A Frohman, J J Kopchick (2009) Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects – Growth Hormone and IGF Research, 2009 Dec, Volume 19 (Issue 6), Pages 471-7.
(6) C Dieguez, V Jordan, P Harris, S Foord, M D Rodriguez-Arnao, A Gomez-Pan, R Hall, M F Scanlon (1986) Growth hormone responses to growth hormone-releasing factor (1-29) in euthyroid, hypothyroid and hyperthyroid rats. The Journal of Endocrinology, 1986 Apr, Volume 109 (Issue 1), Pages 53-6.
(7) R Valcavi, V Jordan, C Dieguez, R John, E Manicardi, I Portioli, M D Rodriguez-Arnao, A Gomez-Pan, R Hall, M F Scanlon (1986) Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine. Clinical Endocrinology (Oxford), 1986 Jun, Volume 24 (Issue 6), Pages 693-8.
(8) A V Schally, X Zhang, R Cai, J M Hare, R Granata, and M Bartoli (2019) Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists – Endocrinology, 2019 Jul 1, Volume 160 (Issue 7), Pages 1600-1612.
(9) T Ito, H Igarashi, T K Pradhan, W Hou, S A Mantey, J E Taylor, W A Murphy, D H Coy, and R T Jensen (2001) GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity – Peptides, 2001 Jul, Volume 22 (Issue 7), Pages 1139-51.